Their strength
A modern, AI-native EMR with embedded RCM and a positioning close to ours, at an earlier stage.
The real cost
Pricing not public — an early-stage company.
Where TurboPT wins
Same strategy, no installed base. The claims history, the ERA volume, and the benchmarking data set are the whole point, and those take decades rather than a funding round.